|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:approvedBy
|
gptkb:France
|
|
gptkbp:ATCCode
|
N05BA05
|
|
gptkbp:availableOn
|
potassium salt
|
|
gptkbp:brand
|
Tranxene
|
|
gptkbp:CASNumber
|
23887-31-2
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
acute narrow-angle glaucoma
severe respiratory insufficiency
sleep apnea syndrome
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:drugClass
|
benzodiazepine
sedative
anticonvulsant
muscle relaxant
hypnotic
|
|
gptkbp:eliminationHalfLife
|
2 hours (parent), 20–179 hours (active metabolite)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasActiveMetabolite
|
nordazepam
|
|
gptkbp:hasINN
|
clorazepate
|
|
gptkbp:hasMolecularFormula
|
C16H11ClN2O3
|
|
gptkbp:hasSMILES
|
C1C(=O)NC2=C(C=C(C=C2)Cl)C(=O)N1C3=CC=CC=C3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clorazepate
|
|
gptkbp:introducedIn
|
1968
|
|
gptkbp:IUPACName
|
7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABAA receptor positive allosteric modulator
|
|
gptkbp:metabolism
|
desmethyldiazepam
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
D (US)
|
|
gptkbp:prodrugOf
|
nordazepam
|
|
gptkbp:proteinBinding
|
97%
|
|
gptkbp:PubChem_CID
|
2806
2704
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:riskOfWithdrawal
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
confusion
dizziness
fatigue
drowsiness
|
|
gptkbp:synonym
|
clorazepate dipotassium
|
|
gptkbp:UNII
|
U5V383OQ2O
|
|
gptkbp:usedFor
|
gptkb:alcohol_withdrawal_syndrome
anxiety disorders
seizure disorders
|
|
gptkbp:bfsParent
|
gptkb:N05BA
|
|
gptkbp:bfsLayer
|
7
|